Method of inhibiting tau phosphorylation
AssigneeCassava Sciences, Inc.
InventorsHoau-Yan WANG, Lindsay BURNS BARBIER
Life of this patent
Estimating the term…
Abstract
A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
Claims30
1-68. (canceled)
A method of inhibiting hyperphosphorylation of a tau protein in a patient, wherein the method comprises administering a compound of the structure:
- or a pharmaceutically acceptable salt and/or solvate thereof to the patient.
A method of inhibiting Filamin A (FLNA)-mediated signaling in a patient, wherein the method comprises administering a compound of the structure:
- or a pharmaceutically acceptable salt and/or solvate thereof to the patient.
A method of inhibiting Aβ-induced α7nAChR-mediated signaling in a patient, wherein the method comprises administering a compound of the structure:
- or a pharmaceutically acceptable salt and/or solvate thereof to the patient.
A method of inhibiting interaction of Aβ with α7nAChR in a patient, wherein the method comprises administering a compound of the structure:
- or a pharmaceutically acceptable salt and/or solvate thereof to the patient.
Dependencies are inferred from the claim text.